Korsana Biosciences is set to go public through a reverse merger with Paragon Therapeutics’ offshoot Korsana, aiming to bring an Alzheimer’s antibody asset into the next stage with additional funding. Following the all-stock transaction, the merged entity will operate under the Korsana brand and seek a Nasdaq ticker switch to KRSA. Korsana’s lead program, KRSA-028, is designed to cross the blood-brain barrier via transferrin receptor binding and is planned to enter a phase 1 study, with amyloid plaque clearance readouts targeted by the end of 2027. Korsana also secured $380 million in private investment from backers including Fairmount and Venrock. The move underscores how late-stage Alzheimer’s candidates using BBB-crossing mechanisms continue to attract capital—particularly when paired with near-term biomarker plans.